Rotavirus (RV) is the leading cause of severe acute gastroenteritis (GE) in infants worldwide. Several vaccines against RV were developed to reduce disease burden, hospitalization rates and health utilization costs. RV GE is a serious disease in preterm (PT) infants, and the administration of RV vaccine to these at-risk subjects at the proper time could have great clinical relevance. However, most data on the efficacy and safety of RV vaccinations were collected in healthy full-term infants, and few studies investigated PT infants. The lack of studies in PT infants may explain why neonatologists in several neonatal intensive care units (NICUs) do not follow the official recommendations, which indicate that RV vaccine may be administered in hospitals. Increasing neonatologists' knowledge on the efficacy and safety of RV vaccines and defining PT candidates for vaccination and the necessary precautions are extremely important to avoid potential vaccine virus transmission and improve RV vaccination coverage in PT infants. Further studies should analyse the impact of vaccination of PT infants of different gestational ages and various clinical histories in stable conditions in the NICU with a careful monitoring of adverse events to the vaccine and RV GE occurrence. Only data that confirm the efficacy and safety of RV vaccines in large numbers of PT infants with different characteristics will convince neonatologists to use RV vaccines in PT infants hospitalized in NICUs.

Rotarix® and RotaTeq® administration to preterm infants in the neonatal intensive care unit : Review of available evidence / S. Esposito, L. Pugni, F. Mosca, N. Principi. - In: VACCINE. - ISSN 0264-410X. - 36:36(2018 Aug 28), pp. 5430-5434.

Rotarix® and RotaTeq® administration to preterm infants in the neonatal intensive care unit : Review of available evidence

S. Esposito
;
L. Pugni;F. Mosca;
2018

Abstract

Rotavirus (RV) is the leading cause of severe acute gastroenteritis (GE) in infants worldwide. Several vaccines against RV were developed to reduce disease burden, hospitalization rates and health utilization costs. RV GE is a serious disease in preterm (PT) infants, and the administration of RV vaccine to these at-risk subjects at the proper time could have great clinical relevance. However, most data on the efficacy and safety of RV vaccinations were collected in healthy full-term infants, and few studies investigated PT infants. The lack of studies in PT infants may explain why neonatologists in several neonatal intensive care units (NICUs) do not follow the official recommendations, which indicate that RV vaccine may be administered in hospitals. Increasing neonatologists' knowledge on the efficacy and safety of RV vaccines and defining PT candidates for vaccination and the necessary precautions are extremely important to avoid potential vaccine virus transmission and improve RV vaccination coverage in PT infants. Further studies should analyse the impact of vaccination of PT infants of different gestational ages and various clinical histories in stable conditions in the NICU with a careful monitoring of adverse events to the vaccine and RV GE occurrence. Only data that confirm the efficacy and safety of RV vaccines in large numbers of PT infants with different characteristics will convince neonatologists to use RV vaccines in PT infants hospitalized in NICUs.
acute gastroenteritis; preterm infants; rotarix; rotateq; rotavirus; rotavirus vaccine; molecular medicine; immunology and microbiology (all); veterinary (all); public health, environmental and occupational health; infectious diseases
Settore MED/38 - Pediatria Generale e Specialistica
28-ago-2018
14-ott-2017
Article (author)
File in questo prodotto:
File Dimensione Formato  
Rotarix and RotaTeq administration to preterm infants in the neonatal.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 321.61 kB
Formato Adobe PDF
321.61 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
1-s2.0-S0264410X17313920-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 304.81 kB
Formato Adobe PDF
304.81 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/549343
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact